AMAG Pharmaceuticals, Inc. (AMAG)
(Delayed Data from NSDQ)
$11.57 USD
+0.34 (3.03%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[AMAG]
Reports for Purchase
Showing records 1 - 20 ( 130 total )
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
FDA Proposes Withdrawal of Makena Approval; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Covis Group to Acquire AMAG for $647M; Downgrade to Neutral, Price Target to $13.75
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the 2020 H.C. Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
COVID-19 Leaves Its Mark in 2Q20 Though Turnaround Seems in Place; Reiterate Buy, Raising PT to $14 from $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
In Another Step Towards Its Heme-Onc Roots, AMAG Divests Vyleesi; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Deal Should Open Eyes to Ciraparantag; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
A Small but Needed First Step as AMAG Charts a Course Back to Its Roots in Hem-Onc
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D